Jian-Xiong Wang1,2, Matthew E Merritt3, A Dean Sherry4,5,6, Craig R Malloy4,5,7,8. 1. Advanced Imaging Research Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA. jian-xiong.wang@utsouthwestern.edu. 2. Department of Radiology, University of Texas Southwestern Medical Center, Dallas, Texas, USA. jian-xiong.wang@utsouthwestern.edu. 3. Department of Biochemistry and Molecular Biology, University of Florida, Gainesville, Florida, USA. 4. Advanced Imaging Research Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA. 5. Department of Radiology, University of Texas Southwestern Medical Center, Dallas, Texas, USA. 6. Department of Chemistry, University of Texas at Dallas, Richardson, Texas, USA. 7. Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA. 8. VA North Texas Health Care System, Dallas, Texas, USA.
Abstract
PURPOSE: Chemical shift imaging (CSI) has long been considered the gold standard method for in vivo hyperpolarized (13) C metabolite imaging because of its high sensitivity. However, CSI requires a large number of excitations so it is desirable to reduce the number of RF excitations and the total acquisition time. METHODS: Centric phase encoding and three-dimensional compressed sensing methods were adopted into a CSI acquisition to improve efficiency and reduce the number of excitations required for imaging hyperpolarized metabolites. The new method was implemented on a GE MR750W scanner for routine real time metabolic imaging experiments. RESULTS: Imaging results from phantoms and in vivo animals using hyperpolarized (13) C tracers demonstrate that when the entire CSI dataset is treated as a single object, compressed sensing can be satisfactorily applied to spectroscopic CSI. Centric k-space trajectory data collection also greatly improves the acquisition efficiency. This combination of compressed sensing CSI and acquisition time reduction was used to perform a hyperpolarized (13) C dynamic study. CONCLUSION: Compressed sensing can be satisfactorily applied to conventional CSI in hyperpolarized (13) C metabolite MR imaging to reduce the number of RF excitations and accelerate the imaging speed to take advantage of conventional CSI in providing high sensitivity and a large spectral bandwidth. Magn Reson Med 76:1033-1038, 2016.
PURPOSE: Chemical shift imaging (CSI) has long been considered the gold standard method for in vivo hyperpolarized (13) C metabolite imaging because of its high sensitivity. However, CSI requires a large number of excitations so it is desirable to reduce the number of RF excitations and the total acquisition time. METHODS: Centric phase encoding and three-dimensional compressed sensing methods were adopted into a CSI acquisition to improve efficiency and reduce the number of excitations required for imaging hyperpolarized metabolites. The new method was implemented on a GE MR750W scanner for routine real time metabolic imaging experiments. RESULTS: Imaging results from phantoms and in vivo animals using hyperpolarized (13) C tracers demonstrate that when the entire CSI dataset is treated as a single object, compressed sensing can be satisfactorily applied to spectroscopic CSI. Centric k-space trajectory data collection also greatly improves the acquisition efficiency. This combination of compressed sensing CSI and acquisition time reduction was used to perform a hyperpolarized (13) C dynamic study. CONCLUSION: Compressed sensing can be satisfactorily applied to conventional CSI in hyperpolarized (13) C metabolite MR imaging to reduce the number of RF excitations and accelerate the imaging speed to take advantage of conventional CSI in providing high sensitivity and a large spectral bandwidth. Magn Reson Med 76:1033-1038, 2016.
Authors: Simon Hu; Michael Lustig; Albert P Chen; Jason Crane; Adam Kerr; Douglas A C Kelley; Ralph Hurd; John Kurhanewicz; Sarah J Nelson; John M Pauly; Daniel B Vigneron Journal: J Magn Reson Date: 2008-03-18 Impact factor: 2.229
Authors: Christoffer Laustsen; Sara Lycke; Fredrik Palm; Jakob A Østergaard; Bo M Bibby; Rikke Nørregaard; Allan Flyvbjerg; Michael Pedersen; Jan H Ardenkjaer-Larsen Journal: Kidney Int Date: 2013-12-18 Impact factor: 10.612
Authors: Klaes Golman; René In't Zandt; Mathilde Lerche; Rikard Pehrson; Jan Henrik Ardenkjaer-Larsen Journal: Cancer Res Date: 2006-11-15 Impact factor: 12.701
Authors: Simon Hu; Michael Lustig; Asha Balakrishnan; Peder E Z Larson; Robert Bok; John Kurhanewicz; Sarah J Nelson; Andrei Goga; John M Pauly; Daniel B Vigneron Journal: Magn Reson Med Date: 2010-02 Impact factor: 4.668
Authors: Klaes Golman; J Stefan Petersson; Peter Magnusson; Edvin Johansson; Per Akeson; Chun-Ming Chai; Georg Hansson; Sven Månsson Journal: Magn Reson Med Date: 2008-05 Impact factor: 4.668
Authors: Menna R Clatworthy; Mikko I Kettunen; De-En Hu; Rebeccah J Mathews; Timothy H Witney; Brett W C Kennedy; Sarah E Bohndiek; Ferdia A Gallagher; Lorna B Jarvis; Kenneth G C Smith; Kevin M Brindle Journal: Proc Natl Acad Sci U S A Date: 2012-07-26 Impact factor: 11.205
Authors: Sarah J Nelson; John Kurhanewicz; Daniel B Vigneron; Peder E Z Larson; Andrea L Harzstark; Marcus Ferrone; Mark van Criekinge; Jose W Chang; Robert Bok; Ilwoo Park; Galen Reed; Lucas Carvajal; Eric J Small; Pamela Munster; Vivian K Weinberg; Jan Henrik Ardenkjaer-Larsen; Albert P Chen; Ralph E Hurd; Liv-Ingrid Odegardstuen; Fraser J Robb; James Tropp; Jonathan A Murray Journal: Sci Transl Med Date: 2013-08-14 Impact factor: 17.956
Authors: Andrew Cho; Justin Y C Lau; Benjamin J Geraghty; Charles H Cunningham; Kayvan R Keshari Journal: J Nucl Med Date: 2017-06-08 Impact factor: 10.057
Authors: Geoffrey J Topping; Christian Hundshammer; Luca Nagel; Martin Grashei; Maximilian Aigner; Jason G Skinner; Rolf F Schulte; Franz Schilling Journal: MAGMA Date: 2019-12-06 Impact factor: 2.310